Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT07294365

A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)

Led by Dizal Pharmaceuticals · Updated on 2026-01-22

60

Participants Needed

1

Research Sites

97 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a Phase 2, open-label, randomized, multicenter study to assess the efficacy and safety of DZD8586 in patients with primary immune thrombocytopenia (ITP). The target population of this study is patients with primary ITP who had failed to respond or relapsed after receiving at least one standard therapy. Participants who meet the inclusion criteria and do not meet the exclusion criteria will be randomized to different dose groups.

CONDITIONS

Official Title

A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female participants 18 years of age or older
  • Diagnosed with persistent or chronic primary ITP with average platelet counts less than 30 × 10⁹/L
  • Have failed at least one standard ITP treatment such as glucocorticoids or IVIG
  • Have adequate bone marrow reserve and organ function
  • Willing to follow contraceptive restrictions
Not Eligible

You will not qualify if you...

  • Evidence of secondary causes of immune thrombocytopenia
  • History of coagulation disorders other than ITP, including disseminated intravascular coagulation, hemolytic uremic syndrome, or thrombotic thrombocytopenic purpura
  • Previous or current treatments prohibited by the study protocol
  • Severe heart abnormalities
  • Active infections
  • Poorly controlled gastrointestinal disorders or inadequate medication absorption
  • Known allergy to DZD8586 or related chemical compounds
  • Pregnant or breastfeeding females

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Qilu Hospital of Shandong University

Jinan, Shandong, China, 250012

Actively Recruiting

Loading map...

Research Team

C

Cong Wei

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here